This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vical's CEO Presents At Bank Of America Merrill Lynch Health Care Conference Call (Transcript)

So Allovectin-7 something that we’ve been working for very long time, we’re pretty excited the pivotal data from this program will be coming out by the end of this year. It’s a systemic immunotherapy, but the beauty of it, it’s given locally. So the fact that it’s given locally, but works systemically does not have the side effects of traditional systemic drugs.

We have treated about 900 patients in variety of cancer applications, its well tolerated. Let me give an example of how it’s given, it’s given in the outpatient setting one injection per week into the lesion and you repeat every week for six weeks in a row followed by two week of observation period.

So one cycle of treatment is about eight weeks, in eight weeks you get six injections. Most patients start showing benefit of the drug after about two cycles of treatment, which is 16 weeks or four months. So, the key thing that you need to understand as you walk through my presentation that in immunotherapy the patients need to live long enough to benefit from immunotherapy.

It has a unique mechanism of action, I’m not going to spend a lot of time talking about it, you can go to our website and look at it. But, I think the most important thing it has potential synergies with currently approved new therapies for melanoma, it has an orphan drug status or fast-track status. With all the U.S. and EU commercial rights and we have an SP or a Special Protocol assessment with the agency.

Our people ask, what’s the melanoma market now that the new two drugs have been approved. There is plenty of room for melanoma. Melanoma is not been cured, the two drugs have benefits, but they have their own toxicity. These kind of patients we’re treating in our Phase 3 trial will represent about third of the vulvar melanoma patients. The current drugs have been priced at $60,000 to $120,000 per therapy, so plenty of room a huge commercial opportunity for a company for our size.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,795.59 -2.90 -0.02%
S&P 500 2,089.28 -0.83 -0.04%
NASDAQ 5,127.0170 -0.5080 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs